Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics

Author: Benzinga Newsdesk | April 09, 2024 08:51am

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field
Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSense
- Lonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of work

Posted In: NRSN